VivoSeq
Oncology

Esophageal Cancer

285

Pipeline Programs↗

90

Active Trials↗

96

Companies Involved↗

Esophageal Cancer is a highly competitive landscape with 285 programs across 96 companies. The most active players are Ganymed Pharmaceuticals GmbH, Adlai Nortye Biopharma Co., Ltd., Oncolys BioPharma Inc. 8 therapies are approved with 58 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

87/100

Pipeline Velocity

39/100

Mech. Concentration

7/100

Completion Rate

78/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Ganymed Pharmaceuticals GmbH

1 program

Phase 1A

Adlai Nortye Biopharma Co., Ltd.

1 program

Phase 1O

Oncolys BioPharma Inc

1 program

Phase 1F

Five Prime Therapeutics, Inc.

1 program

Phase 1Z

Zhejiang Hisun Pharmaceutical Co. Ltd.

1 program

Phase 1A

Azurity Pharmaceuticals

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical15

Platinum

Bristol-Myers Squibb

Sorafenib

Bayer

Tislelizumab

BeiGene

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Risedronate

Vitae Pharmaceuticals Inc., an Allergan affiliate

Phase 141

Pertuzumab

Roche

Tamoxifen

AstraZeneca

Trifluridine and Tipiracil Hydrochloride

Roswell Park Cancer Institute

Akt Inhibitor MK2206

National Cancer Institute (NCI)

Lapatinib Ditosylate

Novartis

Phase 2163

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Irinotecan Hydrochloride

Eastern Cooperative Oncology Group

Serplulimab

Shanghai Henlius Biotech

Retifanlimab

Incyte

Thalidomide

Bristol-Myers Squibb

Phase 358

Epirubicin Hydrochloride

Merck & Co.

Nimotuzumab

Biotech Pharmaceutical Co., Ltd.

Toripalimab

Coherus Oncology, Inc.

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Nedaplatin

Jiangsu Simcere Pharmaceutical Co., Ltd.

Approved8

Propofol

Fresenius Kabi Oncology Ltd.

Ibrutinib

Pharmacyclics LLC.

Olaparib

AstraZeneca

Eflornithine

USWM, LLC (dba US WorldMeds)

Aspirin

Bayer

Analysis

Modality Breakdown

85%

Small molecule

267 of 315 classified programs — the dominant modality here.

15%ALL OTHERSMonoclonal antibody3812%Cell therapy3<1%Protein / enzyme2<1%Vaccine2<1%Antibody–drug conjugate1<1%Peptide1<1%Other1<1%

Small molecule leads; the ring shows all 315 classified programs, each share of the total. Modality classified for 99% of 342 pipeline programs.

Analysis

Trial Status

400

clinical trials

Completed165 · 41%
Unknown status99 · 25%
Recruiting56 · 14%
Terminated31 · 8%
Active, not recruiting19 · 5%
Not yet recruiting15 · 4%
Other15 · 4%

Clinical Trials

Trial Activity

400 trials

Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study
Recruiting·TThe Affiliated Hospital of Putian University·Phase 2·NCT07437898·42 enrolled
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy
Recruiting·—·Phase 2·NCT06084897·120 enrolled
Neoadjuvant Treatment Modalities in Esophageal Cancer
Recruiting·—·Phase 3·NCT04821843·2,000 enrolled
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Recruiting·—·Phase 2·NCT04018872·78 enrolled
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07455019·28 enrolled
Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy
Recruiting·UUniversity of Utah·Phase 1·NCT04846309·16 enrolled
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
Recruiting·FFujian Cancer Hospital·Phase 2·NCT05624099·75 enrolled
Predicting Esophageal Cancer Borders Using PET-Imaging
Recruiting·UUniversity Hospital Heidelberg·Phase 2·NCT06408116·30 enrolled
A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer
Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT06869226·283 enrolled
Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
Recruiting·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT06253650·46 enrolled
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
Recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT05332002·38 enrolled
Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06354218·50 enrolled
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
Recruiting·RRoswell Park Cancer Institute·Phase 1·NCT04511039·45 enrolled
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
Recruiting·—·Phase 3·NCT05188313·376 enrolled
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT04615013·24 enrolled
Page 1 of 27

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)